HC Wainwright reaffirmed their buy rating on shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) in a research note published on Friday morning, Benzinga reports. HC Wainwright currently has a $16.00 target price on the biopharmaceutical company’s stock. Several other analysts have also recently weighed in on the stock. StockNews.com cut shares of Ocular Therapeutix […]
HC Wainwright Reiterates Buy Rating for Ocular Therapeutix (NASDAQ:OCUL) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Ocular Therapeutix (NASDAQ: OCUL) has recently received a number of price target changes and ratings updates: 3/10/2024 – Ocular Therapeutix was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating. 3/2/2024 – Ocular Therapeutix was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating. 2/26/2024 – Ocular […]
Ocular Therapeutix (NASDAQ:OCUL – Free Report) had its price target raised by Piper Sandler from $10.00 to $15.00 in a report issued on Monday, Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock. A number of other equities research analysts also recently commented on the stock. Bank of America started […]
Paradigm Capital Management Inc. NY increased its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 100.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 80,000 shares of the biopharmaceutical company’s stock after acquiring an additional 40,000 shares […]